Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-06-19
2008-03-25
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S298000, C549S433000
Reexamination Certificate
active
07348358
ABSTRACT:
The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.
REFERENCES:
patent: 2004/0186169 (2004-09-01), Larsson et al.
patent: 0 188 248 (1986-07-01), None
patent: 0188248 (1986-07-01), None
patent: 8604062 (1986-07-01), None
patent: 9928347 (1999-06-01), None
patent: WO 99/28347 (1999-06-01), None
patent: 0152826 (2001-07-01), None
patent: WO 01/52826 (2001-07-01), None
patent: WO 2004093781 (2004-11-01), None
U.S. Appl. No. 11/346,294, filed Feb. 3, 2006, Larsson, et al.
U.S. Appl. No. 10/554,399, filed Oct. 24, 2005, Axelson, et al.
International Preliminary Examination Report, Sep. 22, 2003.
European Office Action, Mar. 29, 2004.
European Office Action, Jul. 15, 2004.
European Office Action, Feb. 15, 2005.
M. Novelo, et al., “Cytotoxic Constituents From Hyptis Verticillata1”, Journal of Natural Products, vol. 56, No. 10, pp. 1728-1736, Oct. 1999.
M. Gordaliza, et al., “Antineoplastic and Antiviral of Podophyllotoxin Related Lignans”, Arch. Pharm. (Weinheim), vol. 327, No. 3, pp. 175-179, 1994.
J. Miguel del Corral, et al., “Methyl Ethers of Podophyllotoxin-Rleated Cyclolignans”, Journal of Natural Products, vol. 58, No. 6, pp. 870-877, Jun. 1995.
O. Buchardt, et al., “Thermal Chemistry of Podophyllotoxin in Ethanol and a Comparison of the Cytostatic Activity of the Thermolysis Products”, Journal of Pharmaceutical Sciences, vol. 75, No. 11, Nov. 1986, pp. 1076-1080.
A. San Feliciano, et al., “Antineoplastic and Antiviral Activities of Some Cyclolignans”, Plantya Med., vol. 59,, No. 3, 1993, pp. 246-249.
M. Gordaliza, et al., “Synthesis and Antineoplastic Activity of Cyclolignan Aldehydes”, Eur. J. Med. Chem., vol. 35, Nos. 7 & 8, 2000, pp. 691-698.
M. Gordaliza, et al., “Immunosuppressive Cyclolignans”, J. Med. Chem., 1996, vol. 39, No. 14, pp. 2865-2868.
S. Shashikanth, et al., “Synthesis of Podophyllotoxin and Related Analogs: Part IX. Synthesis of Ethylenedioxy and Indan Analogs of Picropodophyllone and Their Antimitotic Activity”, STN International, File CAPLUS, CAPLUS Accession No. 1996:304556, 1996, vol. 5, No. 3, pp. 185-188.
M. Gordaliza, et al., “Cytotoxic Cyclolignans Related to Podophyllotoxin”, IL Farmaco, vol. 56, No. 4, Apr. 1, 2001, pp. 297-304.
M. Gordalilza, et al., “Antitumor Properties of Podophyllotoxin and Related Compounds”, Current Pharmaceutical Design, 2000, vol. 6, pp. 1811-1839.
A. Girnita, et al., “Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth”, Cancer Research, vol. 64, pp. 236-242, Jan. 1, 2004.
Miriam Novelo et al.: “Cytotoxic constituents from hyptis verticillata” Journal of Natural Products, vol. 56, No. 10, pp. 1728-1736 Oct. 1993.
Marina Gordaliza et al.: “Antineoplastic and antiviral activiral activities of podophyllotoxin related lignans” Arch. Pharm. (WEINSHEIM), vol. 327, No. 3, 175-179 1994.
J.M. Miguel Del Corral et al.: “Methyl ethers of podophyllotoxin-related cyclolignans” Journal of Natural Products, vol. 58, No. 6, pp. 870-877 Jun. 1995.
Ole Buchardt et al.: “Thermal chemistry of podophyllotoxin in ethanol and a comparison of the cytostatic activity of the thermolysis products” Journal of Pharmaceutical Sciences, vol. 75, No. 11, pp. 1076-1080, Nov. 1986.
A. San Feliciano et al.: “Antineoplastic and antiviral activities of some cyclolignans” Planta Medica, vol. 59, No. 3, pp. 246-249 1993.
Marina Gordaliza et al.: “Synthesis and antineoplastic activity of cyclolignan aldehydes” Eur. J. Med. Chem., vol. 35, No. 7 & 8, pp. 691-698 2000.
Marina Gordaliza et al.: “Immunosuppressive cyclolignans” J. Med. Chem., vol. 39, No. 14, pp. 2865-2868 1996.
STN International, File CAPLUS, CAPLUS accession No. 1996:304556, document No. 125:10458 S. Shashikanth et al.: “Synthesis of podophyllotoxin and related analogues: part IX. Synthesis of ethylenedioxy and Indan analogues of picropodophyllone and their antimitotic activity” & Indian Journal of Heterocyclic Chemistry (1996), 5(3), 185-188.
Marina Gordaliza et al.: “Cytotoxic cyclolignans related to podophyllotoxin” Il Farmaco, vol. 56, No. 4, pp. 297-304 Apr. 1, 2001.
First Office Action from The Patent Office of the People's Republic of China, issued Mar. 3, 2006.
Foreign Medicine, Physiology, Pathology Science and Clinical Fasciule, 19(6), 1999, pp. 441-443. (w/English Translation of Related Parts of the Reference Document).
Journal of China University of Science and Technology, vol. 27, No. 1, Mar. 1997, pp. 113-116. (w/English Translation of Related Parts of the Reference Document).
Chemistry Journal of Universities, vol. 18, No. 7, Jul. 1997, pp. 1061-1066. (w/English Translation of Related Parts of the Reference Document).
A. Gimita, et al., “The Insulin-Like Growth Factor-1 Receptor Inhibitor Picropodophyllin Causes Tumor Regresion and Attenuates Mechanism (nvolved In Invasion of Uveal Melanoma Cells”, Cancer Therapy: Preclinical, vol. 12, No. 4, Feb. 15, 2006, pp. 1383-1391.
E. Menu, et al.. “Inhibiting the IGF-1 Receptor Tyrosine Kinase With The Cyclolignan PPP: An In Vitro And In Vivo In The 5T33MM Mouse Model”, Blood, vol. 17, No. 2, Jan. 15, 2006, pp. 655-660.
A. Gimita, et al., “Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth”, Cancer Research, vol. 64, Jan. 1, 2004, pp. 236-242.
Axelson Magnus
Larsson Olle
Andres Janet L.
Axelar AB
Covington Raymond
LandOfFree
Use of cyclolignans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cyclolignans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cyclolignans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3970161